{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:24:10Z","timestamp":1792167850355,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00210-025-03954-x","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T09:13:09Z","timestamp":1740733989000},"page":"8287-8294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A systematic review of efgartigimod as an effective treatment for myasthenic crisis"],"prefix":"10.1007","volume":"398","author":[{"given":"Ping","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"3954_CR1","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K (2022) Current treatment of myasthenia gravis. J Clin Med 11:1597. https:\/\/doi.org\/10.3390\/jcm11061597","journal-title":"J Clin Med"},{"key":"3954_CR2","doi-asserted-by":"publisher","first-page":"9455237","DOI":"10.1155\/2024\/9455237","volume":"2024","author":"O Alhaj Omar","year":"2024","unstructured":"Alhaj Omar O, Diel NJ, Gerner ST, M\u00fcck A, Huttner HB et al (2024) Efgartigimod as rescue medication in a patient with therapy-refractory myasthenic crisis. Case Rep Neurol Med 2024:9455237. https:\/\/doi.org\/10.1155\/2024\/9455237","journal-title":"Case Rep Neurol Med"},{"key":"3954_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.27341","volume":"64","author":"J Ching","year":"2021","unstructured":"Ching J, Richards D, Lewis RA, Li Y (2021) Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis. Musc Nerve 64:483\u2013487. https:\/\/doi.org\/10.1002\/mus.27341","journal-title":"Musc Nerve"},{"key":"3954_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho SM, Li Y (2023) Myasthenic crisis. Muscle Nerve 68:8\u201319. https:\/\/doi.org\/10.1002\/mus.27832","journal-title":"Muscle Nerve"},{"key":"3954_CR5","doi-asserted-by":"publisher","first-page":"e16229","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S et al (2024) Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol 31:e16229. https:\/\/doi.org\/10.1111\/ene.16229","journal-title":"Eur J Neurol"},{"key":"3954_CR6","doi-asserted-by":"publisher","first-page":"578431","DOI":"10.1016\/j.jneuroim.2024.578431","volume":"395","author":"Y Hong","year":"2024","unstructured":"Hong Y, Gao L, Huang SQ, Liu S, Feng S et al (2024) Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series. J Neuroimmunol 395:578431. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578431","journal-title":"J Neuroimmunol"},{"key":"3954_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, Karam C, Peric S et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"3954_CR8","doi-asserted-by":"publisher","first-page":"150767","DOI":"10.1016\/j.tmrv.2023.150767","volume":"38","author":"P Mina-Osorio","year":"2024","unstructured":"Mina-Osorio P, Tran M-H, Habib AA (2024) Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease. Transfus Med Rev 38:150767. https:\/\/doi.org\/10.1016\/j.tmrv.2023.150767","journal-title":"Transfus Med Rev"},{"key":"3954_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/ncn3.12813","volume":"12","author":"Y Morita","year":"2024","unstructured":"Morita Y, Osaki Y, Shogase T, Yoshimoto D, Terada T et al (2024) Effective efgartigimod treatment for severe thymoma-associated myasthenia gravis experiencing myasthenic crisis: a case report. Neurol Clin Neurosci 12:312\u2013315. https:\/\/doi.org\/10.1111\/ncn3.12813","journal-title":"Neurol Clin Neurosci"},{"key":"3954_CR10","doi-asserted-by":"publisher","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, et al. (2019) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database of Systematic Reviews and Implementation Reports Publish Ahead of Print. https:\/\/doi.org\/10.11124\/jbisrir-d-19-00099","DOI":"10.11124\/jbisrir-d-19-00099"},{"key":"3954_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12883-024-03804-y","volume":"24","author":"H Ohara","year":"2024","unstructured":"Ohara H, Kikutsuji N, Iguchi N, Kinoshita M (2024) Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report. BMC Neurol 24:292. https:\/\/doi.org\/10.1186\/s12883-024-03804-y","journal-title":"BMC Neurol"},{"key":"3954_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"Bmj"},{"key":"3954_CR13","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3390\/biomedicines11123180","volume":"11","author":"M Pavlekovics","year":"2023","unstructured":"Pavlekovics M, Engh MA, Lugosi K, Szabo L, Hegyi P et al (2023) Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control. Biomedicines 11:3180. https:\/\/doi.org\/10.3390\/biomedicines11123180","journal-title":"Biomedicines"},{"key":"3954_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/wnl.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE et al (2016) International consensus guidance for management of myasthenia gravis. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/wnl.0000000000002790","journal-title":"Neurology"},{"key":"3954_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/imt-2022-0298","volume":"15","author":"A Sivadasan","year":"2023","unstructured":"Sivadasan A, Bril V (2023) Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis. Immunotherapy 15:553\u2013563. https:\/\/doi.org\/10.2217\/imt-2022-0298","journal-title":"Immunotherapy"},{"key":"3954_CR16","doi-asserted-by":"publisher","first-page":"1418503","DOI":"10.3389\/fimmu.2024.1418503","volume":"15","author":"J Song","year":"2024","unstructured":"Song J, Wang HY, Huan X, Jiang QL, Wu ZT et al (2024) Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol 15:1418503. https:\/\/doi.org\/10.3389\/fimmu.2024.1418503","journal-title":"Front Immunol"},{"key":"3954_CR17","doi-asserted-by":"publisher","first-page":"e16306","DOI":"10.1111\/ene.16306","volume":"31","author":"B Sorrenti","year":"2024","unstructured":"Sorrenti B, Laurini C, Bosco L, Strano CMM, Scarlato M et al (2024) Overcoming therapeutic challenges: successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod. Eur J Neurol 31:e16306. https:\/\/doi.org\/10.1111\/ene.16306","journal-title":"Eur J Neurol"},{"key":"3954_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","volume":"19","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R (2022) Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics 19:897\u2013910. https:\/\/doi.org\/10.1007\/s13311-022-01181-3","journal-title":"Neurotherapeutics"},{"key":"3954_CR19","doi-asserted-by":"publisher","first-page":"109241","DOI":"10.1016\/j.ijscr.2024.109241","volume":"115","author":"S Wang","year":"2024","unstructured":"Wang S, Wang Q, Jin L, Dong J, Ding J (2024) Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: a case report. Int J Surge Case Rep 115:109241. https:\/\/doi.org\/10.1016\/j.ijscr.2024.109241","journal-title":"Int J Surge Case Rep"},{"key":"3954_CR20","doi-asserted-by":"publisher","first-page":"175628642412267","DOI":"10.1177\/17562864241226745","volume":"17","author":"Y Wang","year":"2024","unstructured":"Wang Y, Huan X, Zhu X, Song J, Yan C et al (2024) Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study. Ther Adv Neurol Disord 17:17562864241226744. https:\/\/doi.org\/10.1177\/17562864241226745","journal-title":"Ther Adv Neurol Disord"},{"key":"3954_CR21","doi-asserted-by":"publisher","first-page":"1321058","DOI":"10.3389\/fneur.2024.1321058","volume":"15","author":"K Watanabe","year":"2024","unstructured":"Watanabe K, Ohashi S, Watanabe T, Kakinuma Y, Kinno R (2024) Case report: recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod. Front Neurol 15:1321058. https:\/\/doi.org\/10.3389\/fneur.2024.1321058","journal-title":"Front Neurol"},{"key":"3954_CR22","doi-asserted-by":"publisher","first-page":"175628642412548","DOI":"10.1177\/17562864241254895","volume":"17","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Yang MJ, Luo TC, Du X, Wang ZY et al (2024) Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report. Ther Adv Neurol Disord 17:17562864241254896. https:\/\/doi.org\/10.1177\/17562864241254895","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03954-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03954-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03954-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:51:17Z","timestamp":1752555077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03954-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3954"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03954-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}